100th patient joins ChariotMS trial for multiple sclerosis
The trial is testing whether Mavenclad could benefit upper limb movement in MS patients
Read More
Tag: cladribine
Scotland endorses five new therapies for NHS use
Five new medicines are to be funded by the NHS in Scotland, bringing new treatment options for cancer, multiple sclerosis and rheumatoid arthritis, as well as a new contraceptive.
Read More
NICE backs Merck’s Mavenclad for MS
Merck’s Mavenclad is being backed by the National Institute for Health and Clinical Excellence as an option for treating highly active multiple sclerosis in adults on the NHS.
Read More
New analysis backs benefit-risk profile of Merck’s Mavenclad
Merck has released new data showing a positive benefit-risk profile for its multiple sclerosis drug Mavenclad.
Read More
Merck’s MS pill Mavenclad launched in the UK and Ireland
Merck’s Mavenclad is now available in the UK and Ireland to treat highly active relapsing multiple sclerosis in adults.
Read More
EU nod for Merck’s MS therapy Mavenclad
Merck’s Mavenclad has bagged approval in the European Union, Norway, Liechtenstein and Iceland to treat highly active relapsing multiple sclerosis.
Read More
EMA advisors back eight medicines for approval
Eight medicines have been backed for approval by the European Medicines Agency’s Committee for Medicinal Products for Human Use, including new therapies to treat hepatitis C, multiple sclerosis and cancer.
Read More
EU regulators to take another look at Merck’s MS pill
European regulators have accepted for review Merck’s application to market investigational drug cladribine for the treatment of relapsing-remitting multiple sclerosis.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
